To explore the correlations of botulinum toxin (BT) therapy with dysphagia, we wanted to study a group of cervical dystonia (CD) patients with optimised BT therapy during a prolonged period of time to record their dysphagia frequency, severity and duration, to study potential risk factors and try to avoid it by BT application with ultrasound guidance. BT therapy of 75 CD patients (23 males, 52 females, age 60 ± 12 years, BT total dose 303.5 ± 101.5 uMU) was retrospectively analysed for 1 year. BT therapy was optimised prior to the observation period. Dysphagia was noticed by one fifth of the patients. In those patients, it only occurred in about one third of the injection series. It was never associated with a functional deficit and lasted several days to 2 weeks. It was not related to patient age or gender, BT total dose, BT dose in the sternocleidomastoid muscle, BT dose in the sternocleidomastoid and scalenii muscles, by BT therapy with bilateral sternocleidomastoid muscle injections or BT therapy with abobotulinumtoxinA. Ultrasound guidance was not able to prevent it. Further prospective studies will be necessary to study underlying dystonia associated swallowing abnormalities as a potentially predisposing factor.

为了探讨肉毒杆菌毒素 (BT) 治疗与吞咽困难的相关性，我们想研究一组在较长时间内接受优化 BT 治疗的颈肌张力障碍 (CD) 患者，以记录其吞咽困难的频率、严重程度和持续时间，以研究潜在的危险因素，并尽量通过超声引导下的 BT 应用来避免它。对 75 名 CD 患者（23 名男性，52 名女性，年龄 60±12 岁，BT 总剂量 303.5±101.5 uMU）的 BT 治疗进行了为期 1 年的回顾性分析。在观察期之前优化了 BT 疗法。五分之一的患者注意到吞咽困难。在这些患者中，它只发生在大约三分之一的注射系列中。它从未与功能缺陷相关，并持续了几天到 2 周。它与患者年龄或性别、BT 总剂量、BT 在胸锁乳突肌中的剂量，在胸锁乳突肌和斜角肌中的 BT 剂量，通过双侧胸锁乳突肌注射的 BT 疗法或肉毒杆菌毒素 A 的 BT 疗法。超声引导无法阻止它。需要进一步的前瞻性研究来研究潜在的潜在诱发因素与吞咽异常相关的肌张力障碍。